摘要
目的探讨重组人血管内皮抑素与化疗联合应用于晚期消化道恶性肿瘤治疗的临床疗效。方法选取晚期消化道恶性肿瘤患者56例,随机分为研究组与对照组各28例,研究组给予重组人血管内皮抑素联合化疗,对照组给予单纯的化疗。对两组患者的疗效、生活质量、不良反应进行对比。结果治疗2个周期后,研究组疾病控制率为67.73%,总有效率为25.00%,对照组疾病控制率为53.57%,总有效率为14.29%,研究组的疾病控制率与总有效率均高于对照组,差异有统计学意义(P﹤0.05)。研究组QOL改善稳定率为85.71%,高于对照组的64.29%,差异有统计学意义(P﹤0.05)。研究组白细胞减少、血红蛋白减少、血小板减少、恶心呕吐、肝功能损害、血压升高不良反应的发生率均低于对照组,差异有统计学意义(P﹤0.05)。结论重组人血管内皮抑素与化疗联合应用于晚期消化道恶性肿瘤的治疗优于单纯的化疗,在提高了疗效的同时,降低了不良反应的发生率,并改善了患者的生活质量,值得临床推广。
Objective To investigate the clinical effect of recombinant human endostatin combined with chemotherapy in the treatment of advanced gastrointestinal cancer. Method 56 cases of advanced gastrointestinal cancer were included in this study, and were randomized into study group or control group, with 28 cases in each, the study group was given Endostar ＋ chemotherapy, while the control group was administered with chemotherapy alone. The efficacy, quali- ty of life （QoL） and adverse reactions of both groups were compared. Result After 2 cycles of treatment, the study group had a disease control rate （DCR） of 67.73%, the overall response rate （ORR） was 25.00%, and the DCR and ORR was 53.57% and 14.29% in the control group, respectively, these measures were yet significantly improved in the study group compared with the control group （P〈0.05）; the QoL improvement rate was 85.71% in study group, higher than that of the control group at 64.29%, with significant difference observed （P〈0.05）; the incidence of adverse reactions regarding leukocytopenia, low hemoglobin count, thrombocytopenia, nausea and vomiting, liver dysfunction, elevated blood pressure were significantly lower in the study group （P〈0.05）. Conclusion The combination of recombinant hu- man endostatin and chemotherapy is superior than simple chemotherapy in the treatment of advanced gastrointestinal cancer, with better efficacy and lower incidence of adverse reactions, improving the quality of life of patients, thus making it a clinically applicable regimen.
出处
《癌症进展》
2016年第3期256-258,共3页
Oncology Progress
